Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal

Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier.